Ophthalmology Department, University Hospital of Nice, 30, voie Romaine, 06000 Nice, France.
Ophthalmology Department, University Hospital of Nice, 30, voie Romaine, 06000 Nice, France.
J Fr Ophtalmol. 2024 Jan;47(1):103956. doi: 10.1016/j.jfo.2023.03.042. Epub 2023 Sep 30.
To compare the efficacy and safety of iStent inject® versus 360° selective laser trabeculoplasty (SLT) in patients with early glaucoma undergoing cataract surgery.
A retrospective non-randomized study was conducted in 73 eyes divided into two groups: cataract surgery+intraoperative iStent (n=40) versus cataract surgery+postoperative SLT at one month (n=33). The primary endpoint was intraocular pressure (IOP) lowering≥20% between baseline and 6 months postoperatively. The secondary endpoints were IOP lowering at 1, 6 and 12 months, and the mean number of IOP-lowering medications at 6 and 12 months.
The mean baseline IOP was 19.1 mmHg with no significant difference between groups. The mean baseline number of IOP-lowering medications was higher in the iStent group (n=1.95) compared to the SLT group (n=1.53; P=0.04). At 6 months, 18 (60%) patients in the SLT group and 20 (51%) patients in the iStent group achieved IOP lowering≥20% with no significant difference between groups (P=0.431). At 6 months, no difference in the mean number of IOP-lowering medications was found between groups (-0.92 and -0.89 in the iStent and SLT groups, respectively). Similar results were found at 12 months.
These results suggest similar safety and efficacy of intraoperative iStent and postoperative 360° SLT in lowering IOP and reducing glaucoma eye drops in early glaucoma patients undergoing cataract surgery. Treatment choice should be based on the ophthalmologist's experience and on the cost-benefit ratio.
比较白内障手术中应用 iStent inject®与 360°选择性激光小梁成形术(SLT)治疗早期青光眼的疗效和安全性。
本回顾性非随机研究纳入 73 只眼,分为两组:白内障手术+术中 iStent(n=40)和白内障手术+术后 1 个月 SLT(n=33)。主要终点为术后 6 个月内眼压降低≥20%。次要终点为术后 1、6 和 12 个月时的眼压、6 和 12 个月时平均降眼压药物数量。
平均基线眼压为 19.1mmHg,两组间无显著差异。iStent 组的平均基线降眼压药物数量(n=1.95)高于 SLT 组(n=1.53;P=0.04)。6 个月时,SLT 组 18 例(60%)患者和 iStent 组 20 例(51%)患者眼压降低≥20%,两组间无显著差异(P=0.431)。6 个月时,两组间平均降眼压药物数量无差异(iStent 组和 SLT 组分别减少 0.92 和 0.89)。12 个月时也有相似的结果。
这些结果表明,白内障手术中应用 iStent inject®与术后 360° SLT 降低眼压和减少青光眼滴眼液的效果和安全性相似。治疗选择应基于眼科医生的经验和成本效益比。